Curciarello J O, Corallini O, Adrover R E, Chiera A O, Giammona A M, Barbero R, Apraiz M, Belloni P O, Neumann M, Jmelnitzky A C
HIGA, General San Martín de La Plata, Servicio de Gastroenterología, Argentina.
Acta Gastroenterol Latinoam. 1994;25(5):291-6.
Data from 219 hemodyalized patients receiving attention in our Hospital and other private centers in our city are shown. Mean age was 46.9 (range: 14-85), and 132 were male; mean time under dialysis was 20 months, and subjects received an average of 5 transfusions per patient year. Serological reactivity to HBs Ag, Anti HBs and IgG anti HBc by ELISA were investigated in all of them, and anti HCV by second generation enzimo-immunoassay (EIA II) in 73 HBe Ag/anti HBe system were determined in HBs Ag positive patients and those reactive to anti HCV (EIA II) were confirmed by LIA (immunoblotting of synthetic peptides LIA-TEK Organos Teknica). Recombinant anti HBV vaccine 40 mcg at 0-1 and six month were received by 81 cases without HBV markers in their sera and a protective response was considered when anti HBs titration of 10 mU/ml or more were obtained two months later. Prevalence for anti HBc and anti HBs were 38.8% respectively and that for HBs Ag was 21% with 78% of them reactive for HBs Ag. True reactivity for anti HCV (confirmed by LIA) was present in 35.6%, but it was 9.7% in our Hospital and 54.8% in private units (p < 0.0002). Anti HBs titration was done in 69/81 patients who received anti HBV vaccine, and a protective response in 49% were obtained; the other 12 patients underwent acute hepatitis B during the vaccination period.(ABSTRACT TRUNCATED AT 250 WORDS)
展示了来自本市我院及其他私立中心接受治疗的219例血液透析患者的数据。平均年龄为46.9岁(范围:14 - 85岁),其中132例为男性;平均透析时间为20个月,每位患者每年平均输血5次。对所有患者进行了ELISA法检测乙肝表面抗原(HBs Ag)、乙肝表面抗体(Anti HBs)和乙肝核心抗体IgG(IgG anti HBc),对73例患者采用第二代酶免疫测定法(EIA II)检测丙肝抗体(anti HCV)。对HBs Ag阳性患者及丙肝抗体(EIA II)反应阳性者检测HBe Ag/抗HBe系统,通过合成肽免疫印迹法(LIA - TEK Organos Teknica)进行确认。81例血清中无乙肝病毒标志物的患者在0、1月及6个月时接种了40微克重组乙肝疫苗,2个月后抗HBs滴度达到10 mU/ml或更高则视为产生了保护性反应。抗HBc和抗HBs的患病率分别为38.8%,HBs Ag的患病率为21%,其中78%的HBs Ag反应阳性。经LIA确认的抗HCV实际反应率为35.6%,但在我院为9.7%,在私立单位为54.8%(p < 0.0002)。对69/81例接种乙肝疫苗的患者进行了抗HBs滴度检测,49%的患者产生了保护性反应;另外12例患者在疫苗接种期间发生了急性乙型肝炎。(摘要截选至250字)